# Application of AI and digital health tools in public health management of T2DM: from mechanism prediction to personalized treatment

**Authors:** Chonger Yu

PMC · DOI: 10.3389/fpubh.2026.1756755 · Frontiers in Public Health · 2026-02-17

## TL;DR

AI and digital health tools are transforming T2DM management by enabling precise prediction, personalized treatment, and efficient public health strategies.

## Contribution

This review highlights how AI integrates multi-omics and environmental data to improve T2DM prediction and management, especially in low-resource settings.

## Key findings

- AI reveals key mechanisms like gene–environment interactions and β-cell dysfunction, enhancing early T2DM screening.
- Digital health tools like CGM and mHealth apps improve remote monitoring and personalized treatment adherence.
- AI optimizes public health resource allocation and disease burden assessment for chronic disease control.

## Abstract

Type 2 diabetes mellitus (T2DM) poses a significant global public health challenge, with its prevalence escalating continuously and disproportionately affecting low- and middle-income countries (LMICs), imposing a substantial burden on healthcare systems. Traditional management models have limitations in disease prediction, personalized treatment, and public health intervention. Artificial intelligence (AI) and digital health technologies provide novel insights for precise prediction and intelligent management of T2DM. This review systematically summarizes research progress in AI’s role in deciphering T2DM pathogenesis, personalized treatment, and public health management. By integrating multi-omics and environmental data, AI reveals key mechanisms including gene–environment (G × E) interactions, β-cell dysfunction, and inflammatory pathways, significantly enhancing early screening and risk prediction. In clinical management, AI combined with digital health tools [e.g., continuous glucose monitoring (CGM), wearable devices, and mobile health (mHealth) apps] facilitates remote monitoring, medication optimization, and personalized interventions, improving treatment adherence and health management efficiency. At the public health level, AI optimizes resource allocation and disease burden assessment, promoting chronic disease prevention and control model transformation. Future efforts should prioritize developing low-resource-adapted tools, strengthening data privacy protection tailored to LMICs, and addressing algorithmic fairness and the digital divide to ensure safe, equitable, and sustainable AI application in global T2DM management. Overall, AI and digital health integration is driving T2DM management towards an intelligent and precision-based era, with the potential to reduce disparities in LMICs.

## Linked entities

- **Diseases:** Type 2 diabetes mellitus (MONDO:0005148), T2DM (MONDO:0005148)

## Full-text entities

- **Genes:** CRP (C-reactive protein) [NCBI Gene 1401] {aka PTX1}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, SLC5A2 (solute carrier family 5 member 2) [NCBI Gene 6524] {aka SGLT2}, ALB (albumin) [NCBI Gene 213] {aka FDAHT, HSA, PRO0883, PRO0903, PRO1341}, METTL3 (methyltransferase 3, N6-adenosine-methyltransferase complex catalytic subunit) [NCBI Gene 56339] {aka IME4, M6A, MT-A70, Spo8, hMETTL3}, SIRT3 (sirtuin 3) [NCBI Gene 23410] {aka SIR2L3}, TLR4 (toll like receptor 4) [NCBI Gene 7099] {aka ARMD10, CD284, TLR-4, TOLL}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, INS (insulin) [NCBI Gene 3630] {aka IDDM, IDDM1, IDDM2, ILPR, IRDN, MODY10}, ABCA1 (ATP binding cassette subfamily A member 1) [NCBI Gene 19] {aka ABC-1, ABC1, CERP, HDLCQTL13, HDLDT1, HPALP1}, GLP1R (glucagon like peptide 1 receptor) [NCBI Gene 2740] {aka GLP-1, GLP-1-R, GLP-1R}, IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}, SIRT6 (sirtuin 6) [NCBI Gene 51548] {aka SIR2L6, hSIRT6}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, TCF7L2 (transcription factor 7 like 2) [NCBI Gene 6934] {aka TCF-4, TCF4}, IL18 (interleukin 18) [NCBI Gene 3606] {aka IGIF, IL-18, IL-1g, IL1F4}, SIRT1 (sirtuin 1) [NCBI Gene 23411] {aka SIR2, SIR2L1, SIR2alpha}
- **Diseases:** albuminuria (MESH:D000419), mobility impairments (MESH:D014086), hyperglycemic (MESH:D006944), hypertension (MESH:D006973), malnutrition (MESH:D044342), diabetes complications (MESH:D048909), end-stage renal disease (MESH:D007676), COVID-19 (MESH:D000086382), diabetic retinopathy (MESH:D003930), myocardial infarction (MESH:D009203), cardiovascular disease (MESH:D002318), infection (MESH:D007239), IFG (MESH:D007003), diabetes neuropathy (MESH:D003929), insulin resistance (MESH:D007333), age (MESH:D019588), urinary tract infections (MESH:D014552), kidney disease (MESH:D007674), T2DM (MESH:D003924), Systemic (MESH:D015619), beta-cell dysfunction (MESH:D007340), peripheral sensory neuropathy (MESH:D010523), foot ulcer (MESH:D016523), diabetic nephropathy (MESH:D003928), chronic (MESH:D002908), infectious disease (MESH:D003141), neuropathy (MESH:D009422), cognitive impairment (MESH:D003072), disabilities (MESH:D009069), -cell (MESH:D002292), hyperglycemia (MESH:D006943), neurodegenerative diseases (MESH:D019636), Disease (MESH:D004194), Inflammatory (MESH:D007249), periodontitis (MESH:D010518), MDR-TB (MESH:D018088), pain (MESH:D010146), Diabetes (MESH:D003920), beta-cell failure (MESH:D051437), renal function decline (MESH:D060825), chronic kidney disease (MESH:D051436), pancreatic beta-cell dysfunction (MESH:D010195), prediabetes (MESH:D011236), liver fibrosis (MESH:D008103), gestational diabetes mellitus (MESH:D016640), hypo (MESH:D052456), obesity (MESH:D009765), weight gain (MESH:D015430), AI (MESH:C538142), retinopathy (MESH:D058437), acute kidney injury (MESH:D058186), function (MESH:D003291), DL (MESH:D007859), food insecurity (MESH:D005517), hypoglycemic (MESH:C000721848), metabolic disease (MESH:D008659), XAI (MESH:C538243)
- **Chemicals:** A1c (-), sodium (MESH:D012964), amino acids (MESH:D000596), carbohydrate (MESH:D002241), CO2 (MESH:D002245), lipid (MESH:D008055), 1,25(OH)2D3 (MESH:D002117), folic acid (MESH:D005492), creatinine (MESH:D003404), glucose (MESH:D005947), vitamin D (MESH:D014807), imidazole propionate (MESH:C018976), carbon (MESH:D002244), blood glucose (MESH:D001786)
- **Species:** Homo sapiens (human, species) [taxon 9606], Severe acute respiratory syndrome coronavirus 2 (no rank) [taxon 2697049]
- **Mutations:** 69C > T, (AUC) of 0

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12953431/full.md

## Figures

11 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12953431/full.md

## References

164 references — full list in the complete paper: https://tomesphere.com/paper/PMC12953431/full.md

---
Source: https://tomesphere.com/paper/PMC12953431